Multiple Myeloma — Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Citation(s)
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma